TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An update from Futura Medical ( (GB:FUM) ) is now available.
Futura Medical plc announced that Lombard Odier Asset Management, associated with Non-Executive Director Harmesh Suniara, sold 4,441,678 ordinary shares in the company. This transaction reduces Lombard Odier’s holding to 26.90% of Futura’s issued share capital. The sale may impact the company’s market perception and stakeholder confidence, as it involves a significant shareholder reducing its stake.
The most recent analyst rating on (GB:FUM) stock is a Buy with a £140.00 price target. To see the full list of analyst forecasts on Futura Medical stock, see the GB:FUM Stock Forecast page.
More about Futura Medical
Futura Medical plc is a consumer healthcare group specializing in the development and global commercialization of innovative and clinically proven sexual health products. The company’s core strength lies in research, development, and commercialization of topically delivered gel formulations, with its lead product Eroxon® being a topical gel treatment for erectile dysfunction. Futura has established distribution partnerships in major markets including the US and Europe.
Average Trading Volume: 2,349,347
Technical Sentiment Signal: Sell
Current Market Cap: £6.73M
For an in-depth examination of FUM stock, go to TipRanks’ Overview page.